Retatrutide
retatriple agonist
Triple-agonist (GLP-1 / GIP / glucagon). Strongest weight-loss in trials; titration + safety guidance.
- Half-life
- 6.0 d
- Out of system
- ~4 weeks
- Route
- Subcutaneous
- Level
- Advanced
Long-acting — weekly dosing keeps levels steady. After the last dose, roughly 97% has cleared in ~4 weeks (five half-lives) — the window that matters for washouts, bloodwork and surgery.
What Retatrutide is used for
- Triple agonist (GLP-1 / GIP / glucagon) — strongest weight loss in trials so far
- ~24% body weight loss at 48 weeks in phase-2
- Glucose control + lipid improvements
How it's typically used
Trial titration: 2 → 4 → 8 mg weekly. Not approved — follow a clinician if you must use.
What to watch for
- Still in trials — long-term safety unknown
- GI side effects expected; titration matters
- Not commercially available; grey-market sourcing is risky
- TRIUMPH-1 (May 2026) showed ~28% weight loss at 80 weeks, but it is still NOT FDA-approved as of mid-2026 (filing expected late 2026).
About GLP-1 & weight loss
- What they are
- Incretin analogues — GLP-1 and dual/triple agonists. They slow stomach emptying and act on appetite centres in the brain, so you eat less without white-knuckling it.
- How they're run
- One subcutaneous shot a week for most, on the same day each week. Doses climb in steps every four weeks; that slow titration is what keeps side effects tolerable.
- What to watch
- Nausea, constipation, and reflux are near-universal in the first month. Muscle is lost alongside fat unless you keep protein high and keep lifting. Tell any surgeon or anaesthetist you are on one.
Full guide
Retatrutide: Tracking a Triple-Agonist Weight-Loss Compound
What Retatrutide is, how the GLP-1 / GIP / glucagon mechanism differs from single-agonists, and how to track titration and side effects honestly.
Other glp-1 & weight loss
Peptid AI is an educational and self-tracking tool — not a medical service, and not a vendor. Nothing here is medical advice, a prescription, or an endorsement. Doses reflect what is commonly reported in research literature; they are not recommendations. Many compounds listed are experimental, not approved for human use, and/or controlled substances that are illegal to possess without a prescription in many countries. Always consult a qualified physician before starting, changing, or stopping any protocol.